Skip to main content
ERAS
NASDAQ Life Sciences

Erasca 和 Tango Therapeutics启动临床合作，共同开发联合癌症治疗方法

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
8
Price
$15.15
Mkt Cap
$4.681B
52W Low
$1.01
52W High
$15.27
Market data snapshot near publication time

summarizeSummary

Erasca 和 Tango Therapeutics 已宣布达成临床合作和供应协议，以评估 Erasca 的泛RAS分子胶水 ERAS-0015 与 Tango 的 PRMT5 抑制剂 vopimetostat (TNG462) 的联合使用。这一合作将支持一项针对MTAP缺失的胰腺癌或MTAP缺失的RAS突变非小细胞肺癌患者的1/2期临床试验，解决一个重大未被满足的医疗需求。Erasca 将无偿提供 ERAS-0015，而 Tango 将赞助临床试验。这一合作是 Erasca的一个重要的产品线开发，通过一种新型的联合方法扩大其关键资产 ERAS-0015 的潜在临床应用和市场。投资者将密切关注这一1/2期试验的初步数据，因为积极的结果可能会显著降低两种化合物的风险，并验证双重靶向策略。

在该公告发布时，ERAS的交易价格为$15.15，交易所为NASDAQ，所属行业为Life Sciences，市值约为$46.8亿。 52周交易区间为$1.01至$15.27。 这则新闻被评估为积极市场情绪，重要性评分为8/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed ERAS - Latest Insights

ERAS
Apr 28, 2026, 3:58 PM EDT
Source: Dow Jones Newswires
Importance Score:
9
Cancer Trial Patient Death Sends Erasca Shares Down 48% After Update
Sentiment: Negative
View Wiseek Article
ERAS
Apr 27, 2026, 4:17 PM EDT
Filing Type: 8-K
Importance Score:
9
Erasca Reports Strong Phase 1 Data for Pan-RAS Molecular Glue ERAS-0015 in Solid Tumors
Sentiment: Positive
View Wiseek Article
ERAS
Apr 27, 2026, 8:31 AM EDT
Filing Type: 8-K
Importance Score:
8
Erasca Faces Patent Infringement Lawsuit Over Key Drug Candidate ERAS-0015
Sentiment: Negative
View Wiseek Article
ERAS
Apr 21, 2026, 9:10 AM EDT
Filing Type: 8-K
Importance Score:
7
Erasca Narrows Data Readout Window for Pan-RAS Molecular Glue ERAS-0015 to Mid-May 2026
Sentiment: Positive
View Wiseek Article
ERAS
Mar 12, 2026, 4:11 PM EDT
Filing Type: 10-K
Importance Score:
8
Erasca Secures $242.7M in Public Offering, Extends Runway to H2 2028, and Expands ERAS-0015 Rights
Sentiment: Positive
View Wiseek Article
ERAS
Mar 12, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Erasca Reports Q4/FY25 Results, Extends Cash Runway, and Reveals Positive ERAS-0015 Clinical Data
Sentiment: Positive
View Wiseek Article
ERAS
Mar 12, 2026, 4:01 PM EDT
Source: Reuters
Importance Score:
7
Erasca Reports Q4 Net Loss of $29.1M, Basic EPS at -$0.1
Sentiment: Negative
View Wiseek Article
ERAS
Mar 10, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Erasca Secures Worldwide Rights for Promising ERAS-0015 Pan-RAS Drug, Expanding Market to China
Sentiment: Positive
View Wiseek Article
ERAS
Mar 05, 2026, 7:01 AM EST
Source: GlobeNewswire
Importance Score:
8
Erasca and Tango Therapeutics Launch Clinical Collaboration for Combination Cancer Therapy
Sentiment: Positive
View Wiseek Article
ERAS
Jan 29, 2026, 4:30 PM EST
Filing Type: 8-K
Importance Score:
8
Erasca Closes $242.7M Public Offering, Extends Cash Runway into First Half of 2029
Sentiment: Positive
View Wiseek Article